Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Maria Debora De Pasquale und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncohematology, Hemopoietic Transplantation, Cellular Therapies and Clinical Trials, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Wilms Tumor, Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background
While Wilms tumor (WT) typically has a favorable prognosis, relapsed cases—especially those with high‐risk histology—remain therapeutically challenging after intensive frontline therapy. The combination of vincristine and irinotecan has demonstrated activity in pediatric solid tumors, and pazopanib, a multi‐targeted tyrosine kinase inhibitor, might enhance treatment efficacy through antiangiogenic mechanisms.
Methods
This report included six children with relapsed WT treated between 2015 and 2022 at Bambino Gesù Children's Hospital, Rome. All patients had received prior multimodal therapy, including six chemotherapeutic agents. The VIPaz regimen (vincristine, irinotecan, pazopanib) was administered as second‐ or third‐line therapy in combination with surgery and/or radiotherapy. Treatment response and toxicity were evaluated.
Results
Five out of six patients (83%) responded to the treatment. Three (50%) achieved complete remission and remained disease‐free at 27, 74, and 76 months post‐treatment. VIPaz was generally well‐tolerated. No Grade >3 toxicities were observed.
Conclusion
VIPaz in combination with surgery and/or radiotherapy demonstrated an acceptable safety profile and durable responses in 50% of heavily pretreated patients with relapsed high‐risk WT. Although limited by small sample size and retrospective design, these findings support further prospective evaluation of pazopanib‐based regimens and biomarker‐driven approaches in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncohematology, Hemopoietic Transplantation, Cellular Therapies and Clinical Trials, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Surgical Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Diagnostic Radiology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Pathology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
ORCID-Profile: Maria Debora De Pasquale, Alessandro Crocoli, Giuseppe Maria Milano, Ida Russo
Förderung
- Italian Ministry of Health
Zitieren
APA
De Pasquale, M. D., Crocoli, A., Milano, G. M., Paolo, P. D., Camassei, F. D., Russo, I., & Serra, A. (2026). Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70020
Vancouver
De Pasquale MD, Crocoli A, Milano GM, Paolo PD, Camassei FD, Russo I, et al. Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70020
BibTeX
@article{DePasquale2026,
author = {De Pasquale, Maria Debora and Crocoli, Alessandro and Milano, Giuseppe Maria and Paolo, Pierluigi Di and Camassei, Francesca Diomedi and Russo, Ida and Serra, Annalisa},
title = {Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70020}
}
EUVIMED